NanoViricides, Inc. (the “Company”) reports that its CEO, Dr. Eugene Seymour, MD, MPH, will be presenting at the LD Micro Invitational Conference today at 5pm Pacific Time at the Luxe Sunset Boulevard Hotel in West Los Angeles.
Dr. Seymour will provide an update on the Company’s drug programs, and the cGMP clinical product manufacturing facility.
This facility in Shelton, CT, is nearing completion of the construction phase and is entering the facility validation phase. The fully customizable manufacturing facility will enable cGMP manufacture of all of our nanoviricides® drug candidates in kilogram scale, sufficient for pre-IND and human clinical studies.
The Company intends to begin the safety/toxicology studies of its Injectable FluCide™ drug candidate as soon as feasible. The Company is in the process of producing sufficient drug substance for these studies at its existing facility. This injectable FluCide drug candidate is intended to treat hospitalized patients with influenza. It is designed to be broad-spectrum, and thus is expected to work against most, if not all, forms of influenza virus, including epidemic, pandemic (e.g. H1N1/2009), high path influenzas such as H3N2, H7N9, and “bird flu” such as H5N1. This drug candidate has demonstrated an unparalleled 1,000-fold reduction in lung viral load in a lethal animal model study. In the same study, the current standard of care, oseltamivir, (Tamiflu®, Roche) exhibited only a 2-fold reduction in lung viral load at the same time point.
The Company is working on five additional commercially important drug candidates, namely: DengueCide™, HerpeCide™, HIVCide™, Oral FluCide™ for out-patients, and a broad-spectrum antiviral drug for viral diseases of the external eye. All of our programs are for therapeutics to treat viral infections. Our drugs are expected to be useful as prophylactics as well.
DengueCide has recently received orphan drug designation by the US FDA as well as the European EMA.
NanoViricides recently received an important international award, the “IAIR Award 2014 for Leadership in Nanomedicines in the North American Sector”.
The market size for our first drug, injectable FluCide, for use in hospitalized patients with influenza, is estimated to be in excess of a billion dollars. There is no satisfactory treatment available for this indication at present. In addition, the overall influenza market is expected to be in several billions of dollars. The total market size addressed by the Company’s current drug programs is estimated at about $40 billion or more.
The Company currently has approximately $36.6 million cash-in-hand and cash-like-instruments. These funds are estimated to be sufficient for taking at least one of our drug candidates through initial human clinical trials, and possibly take another drug candidate into human clinical trials.
Dr. Seymour’s presentation will be made available on our website (www.nanoviricides.com).
About LD Micro:
is LD Micro is a newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. LD Micro concentrates on finding, researching, and investing in companies that are often overlooked by institutional investors. It is a non-registered investment advisor. For more information or to register for the event, please visit www.ldmicro.com or call (408) 457-1042.
About NanoViricides:
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
Source: http://www.nanoviricides.com/